India is building a wider safety net for transplant medicines with a dedicated Biovigilance Programme to strengthen adverse-event monitoring and patient safety.
World Alzheimer’s Day 2026 highlights why early diagnosis matters as new Alzheimer’s treatments emerge and timely care becomes increasingly important.
Ayurveda needs stronger research, scientific validation, and safety monitoring to build a credible pipeline from traditional knowledge to market-ready products.
Congo's Ebola vaccination drive is testing how quickly pharma can turn vaccine research into real-world outbreak protection.
Novo Nordisk loses its obesity-drug lead as Lilly gains ground, raising questions over pipeline depth, patent expiry and future growth.
Regulatory watch intensifies as the EU and FDA clear new treatments while India rewires sterile-drug licensing, digital regulation and CDSCO capacity.
This Week in Biosimilars highlights oncology taking the Lead in India as Dr. Reddy’s enters the nivolumab market and competition expands patient access.
Merck joins India’s crowded biomanufacturing push as global life-science suppliers expand local capacity, training infrastructure and customer support.
AstraZeneca’s England approval of Enhertu signals wider access to cancer care, expanding NHS treatment options for eligible breast cancer patients.
Science still finds insufficient evidence to support stem cell therapy as standard care for autism, keeping the treatment within clinical trials.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")